Recombinant Cynomolgus Monkey Mer Fc Chimera Protein, CF

2 μg/lane of Recombinant Cynomolgus Monkey Mer Fc Chimera Protein (Catalog # 10576-MR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 118-140 kDa and 236-280 kDa, respectively.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey Mer Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Cynomolgus Monkey Mer Fc Chimera (Catalog # 10576-MR) is immobilized at 2 μg/mL, 100 μL/well, Recombinant Human Protein S/PROS1 (Catalog # 9489-PS) binds with an ED₅₀ of 2-10 μg/mL
• Source: Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey Mer protein
  

  Cynomolgus Monkey Mer (Ala23-Ala501) Accession # XP_005575320.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005575320.1
• N-terminal Sequence: Ala23
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 79 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 118-140 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey Mer Fc Chimera Protein, CF

• c-Eyk
• c-mer proto-oncogene tyrosine kinase
• C-mer
• EC 2.7.10
• EC 2.7.10.1
• MER receptor tyrosine kinase
• Mer
• MerTK
• MGC133349
• Receptor tyrosine kinase MerTK
• RP38Proto-oncogene c-Mer
• STK kinase
• tyrosine-protein kinase Mer

Background

Tyrosine-protein Kinase Mer, also known as c-Mer and MerTK, is a member of the receptor tyrosine kinase subfamily TAM (Tyro3, Axl, and Mer). Mature cynomolgus Mer consists of 484 amino acid (aa) extracellular domain (ECD), a 20 aa transmembrane segment, and a 472 aa cytoplasmic domain. Within the ECD, cynomolgus Mer shares 95% and 99% sequence identity with human and rhesus monkey, respectively. Similar to Axl and Tyro3, the ECD of Mer contains two Ig-like motifs and two fibronectin type III motifs. Mer is not expressed in normal B- and T-cells but is expressed in neoplastic B- and T-cell lines (1-2).  It also shows higher expression in immunosuppressive M2‑like macrophages (3).  Mer is known to bind Gas6, Protein S, Tubby, Tubby-like protein 1 (Tulp1), and Galectin-3 (4-7). Binding of Gas6 lead to cell proliferation, migration or the prevention of apoptosis. Upon binding ligands via the Ig-like motif, Mer is dimerized to trans-autophosphorylate the kinase domain to induce downstream signaling. It has been shown that Mer signaling in macrophages induces M2 polarization, which promotes tumor growth, metastasis and evasion of anti-tumor immunity in tumor microenviroment (8). Inhibition of Mer, especially on leukocytes and macrophages, is an effective anti-cancer therapy (9).

1. Graham, D.K. et al. (1994) Cell Growth Differ. 5:647.
2. Graham, D.K. et al. (2006) Clin. Cancer Res. 12:2662.
3. Shibata, T. et al. (2014) J. Immunol. 192:3569.
4. Nagata, K. et al. (1996) J. Biol. Chem. 271:30022.
5. Uehara, H. et al. (2008) J. Immunol. 180:2522.
6. Caberoy, N.B. et al. (2010) EMBO J. 29:3898.
7. Caberoy, N.B. et al. (2012) J. Cell Physiol. 227:401.
8. Kim, S.Y. et al. (2016) Sci. Rep. 6:29673.
9. Cummings, C.T. et al. (2013) Clin. Cancer Res. 19:5275.

Bioinformatics

• Uniprot:
  • XP_005575320.1()